BPC-157 for Sale: What a Lyophilised Vial Must Declare

BPC-157 for sale covers at least five different physical products, and the differences matter more than the price gaps between them. A single vial, a two-peptide blend, a multi-compound stack, a pre-mixed solution, and an oral presentation are not variations on one purchase.

They differ in what a document can honestly cover. A certificate describes a batch of dry powder tested on a date, so the further a format sits from that description, the less any certificate attached to it means. That is the sorting principle used below.

BPC-157 for sale: five formats and what each can be asked to prove

The single-compound lyophilised vial is the format the analytical toolkit was built for. One peptide, dry, in a sealed container, with a lot number: chromatography, mass spectrometry, Karl Fischer water, and an endotoxin assay all apply cleanly, and a certificate can be read against the label without interpretation.

Blends are the next step out. A two-peptide vial such as BPC-157 with TB-500 needs its certificate to name and quantify both components, because a chromatogram of a mixture shows two main peaks and a purity figure for the vial as a whole answers a question nobody asked. Larger multi-peptide products sold under names such as GLOW and KLOW carry BPC-157 alongside other compounds, and the same rule applies with more peaks: what has to be shown is the identity and content of each component, not a single number for the blend. A blend is a formulation decision, and it is only as verifiable as its least documented ingredient.

Pre-mixed solutions are where documentation and product part company. Lyophilisation exists because peptides in water degrade: hydrolysis, oxidation, and adsorption to glass or plastic all proceed at rates that depend on temperature, pH, and time, none of which the buyer can reconstruct for a vial that has been shipped as a liquid. A certificate issued on dry powder at manufacture does not describe that vial. Oral capsules and intranasal sprays sit in a separate category again, because they make a delivery claim on top of an identity claim, and the only registered human study of an oral BPC-157 tablet, a Phase 1 pilot in 42 healthy volunteers registered in 2015, still carries an unknown status and no posted results.

Listing claims and the record that would settle each one

Every phrase in the left-hand column appears on real listings. None of them is self-verifying, and most have a specific document that would settle the question in one step.

The salt row is the one most often waved through. Peptides purified by reversed-phase chromatography usually come out as trifluoroacetate salts, and the counterion is part of the mass in the vial. BPC-157 carries one lysine and a free N-terminal amine, so it binds fewer equivalents than a strongly basic peptide, but even one equivalent is roughly 7 percent of the labelled mass. A listing that names the salt form lets a buyer correct the arithmetic; one that claims a salt improves stability without publishing a stability study has made two claims and supported neither.

One more row belongs in spirit if not in the table: the quantity claim on multi-vial offers. A search for bpc-157 peptide for sale surfaces bundle listings whose per-vial price falls with volume, and volume changes nothing about the documents. Ten vials from one lot share one certificate, which is fine and worth knowing, while ten vials drawn from three lots need three, and a seller who cannot say which case applies has not tracked its own stock closely enough for the certificates to mean much.

The eight fields a BPC-157 listing has to declare

A listing is checkable when it declares enough for someone else to check it. For this compound that means the compound name and the CAS number 137525-51-0, the sequence GEPPPGKPADDAGLV, the nominal mass per vial, the salt form, the lot number, the physical state, the storage condition, and a research-use statement that the rest of the page does not contradict.

Two of those eight do more work than the others. The sequence is what a mass spectrum is compared against, and the theoretical average mass of C62H98N16O22 is about 1419.5 g/mol, so a listing that omits the sequence has removed the reference point for its own identity claim. The lot number is what connects the certificate to the vial, and without it the document floats free of the product. Anyone comparing bpc-157 peptides for sale across several storefronts will find that the fields missing are consistent: sequence, salt, and lot go first.

The research-use statement matters for a different reason. Because BPC-157 has no USP or NF monograph and no marketing authorisation anywhere, the seller has no lawful basis to describe it as a treatment. A page that carries a research-use disclaimer and a dosing chart at the same time has told you which of the two it means. Peer-reviewed work on peptide impurities is the technical backdrop here: deletion sequences, oxidation products, and isomers are ordinary synthesis outcomes, and disclosure is what allows a buyer to see whether anyone looked for them.

The two listings on this page, stated plainly

Ascension Peptides, the vendor on the card above, sells BPC-157 in two of the five formats, and the card carries affiliate links, which is disclosed there. The single vial is 10 mg of lyophilised powder listed at $49.00, which the code PEPTIDEDECK halves to $24.50, giving $2.45 per milligram before any correction for water or counterion.

The second listing is the Wolverine Stack at $90.00, halved to $45.00. It is BPC-157 10 mg combined with TB-500 10 mg, which is 20 mg of peptide across two compounds, so the $2.25 per milligram figure describes the pair. It is not cheaper BPC-157. For a buyer with no interest in TB-500, the single vial is the cheaper way to obtain 10 mg of BPC-157, and the arithmetic only favours the stack if both compounds are wanted. The vendor publishes certificates from two independent laboratories per lot, Kovera Labs on batch #12-05260628 and MZ Biolabs on batch #12-01260229; we have not commissioned or repeated that testing. Quantity tiers take 3, 5, or 10 percent off list, and free carriage starts at $250. The full cost comparison sits in our price breakdown, and the sourcing criteria in the supplier checklist.

Why none of it is sold as a medicine

Every listing described here is a research-material listing, and that is not a formality. BPC-157 has never been approved by FDA for any indication and has no USP or NF monograph. It was placed in FDA's Category 2 for compounding bulk substances in September 2023, removed from that category in April 2026 after the nominations were withdrawn, and narrowly recommended for the 503A Bulks List by the Pharmacy Compounding Advisory Committee on 23 and 24 July 2026. That recommendation is non-binding, the substance is not listed in 21 CFR 216.23, and FDA has issued no final determination, so no approved or compounded product exists to compare a listing against. It is also prohibited at all times in sport under WADA class S0.

Format does not change the evidence grade

A well-documented vial is still a vial of a compound whose effects have been shown in rodents and cells. The tendon work most often cited on listings, including studies reporting effects on tendon fibroblast outgrowth and growth hormone receptor expression, was done in cell culture and rats, and a large share of the wider literature comes from one group at the University of Zagreb.

No large human efficacy trial has been completed, and the first controlled test is now running: a randomised, double-blind, placebo-controlled Phase 2 study of 120 participants in acute hamstring strain, recruiting since 2 February 2026, with estimated primary completion on 14 February 2027. Pending is the accurate grade, not absent. Anyone comparing bpc 157 for sale listings on the strength of the claims printed beside them should grade those claims as preclinical, whatever format the vial takes. Our BPC-157 overview and its mechanism article set out what the preclinical work does and does not support.